APA (7th ed.) Citation

CP, C., S, H., RA, H., BM, S., H, E., G, P., . . . Investigators, D. (2007). Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. Journal of the American College of Cardiology (JACC), 50(19), 1844. https://doi.org/10.1016/j.jacc.2007.07.053

Chicago Style (17th ed.) Citation

CP, Cannon, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, and DISPERSE-2 Investigators. "Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared with Clopidogrel, in Patients with Non-ST-segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial." Journal of the American College of Cardiology (JACC) 50, no. 19 (2007): 1844. https://doi.org/10.1016/j.jacc.2007.07.053.

MLA (9th ed.) Citation

CP, Cannon, et al. "Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared with Clopidogrel, in Patients with Non-ST-segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial." Journal of the American College of Cardiology (JACC), vol. 50, no. 19, 2007, p. 1844, https://doi.org/10.1016/j.jacc.2007.07.053.